OBJECTIVE: To determine whether the free light chain (FLC) assay provides prognostic information relevant to the general population. METHODS: After excluding persons with a known plasma cell disorder, we studied 15,859 Olmsted County, Minnesota, residents 50 years or older in whom unmasked data and samples for FLC testing were available. Baseline information was obtained between March 13, 1995, and November 21, 2003, and follow-up status and cause of death were identified through June 30, 2009. The κ and λ FLC sum (Σ FLC) was evaluated for its ability to predict overall survival. Specific causes of death were also investigated. RESULTS: In 158,003 person-years of follow-up, 4348 individuals died. A high Σ FLC was significantly predictive of worse overall survival; the risk ratio for death for those with the highest decile of Σ FLC (ie, ≥ 4.72 mg/dL) was 4.4 (95% confidence interval, 4.1-4.7) relative to the remaining study participants. Multivariate analyses demonstrated that this excess risk of death was independent of age, sex, and renal insufficiency, with a corrected risk ratio of 2.1 (95% confidence interval, 1.9-2.2). The increased mortality was not restricted to any particular cause of death because the observed-to-expected risk of death from most causes was significantly higher among those individuals with an antecedent Σ FLC of 4.72 mg/dL or higher, which is near the upper limit of normal for the test. CONCLUSION: A nonclonal elevation of Σ FLC is a significant predictor of worse overall survival in the general population of persons without plasma cell disorders.
OBJECTIVE: To determine whether the free light chain (FLC) assay provides prognostic information relevant to the general population. METHODS: After excluding persons with a known plasma cell disorder, we studied 15,859 Olmsted County, Minnesota, residents 50 years or older in whom unmasked data and samples for FLC testing were available. Baseline information was obtained between March 13, 1995, and November 21, 2003, and follow-up status and cause of death were identified through June 30, 2009. The κ and λ FLC sum (Σ FLC) was evaluated for its ability to predict overall survival. Specific causes of death were also investigated. RESULTS: In 158,003 person-years of follow-up, 4348 individuals died. A high Σ FLC was significantly predictive of worse overall survival; the risk ratio for death for those with the highest decile of Σ FLC (ie, ≥ 4.72 mg/dL) was 4.4 (95% confidence interval, 4.1-4.7) relative to the remaining study participants. Multivariate analyses demonstrated that this excess risk of death was independent of age, sex, and renal insufficiency, with a corrected risk ratio of 2.1 (95% confidence interval, 1.9-2.2). The increased mortality was not restricted to any particular cause of death because the observed-to-expected risk of death from most causes was significantly higher among those individuals with an antecedent Σ FLC of 4.72 mg/dL or higher, which is near the upper limit of normal for the test. CONCLUSION: A nonclonal elevation of Σ FLC is a significant predictor of worse overall survival in the general population of persons without plasma cell disorders.
Authors: Angela Dispenzieri; Jerry A Katzmann; Robert A Kyle; Dirk R Larson; L Joseph Melton; Colin L Colby; Terry M Therneau; Raynell Clark; Shaji K Kumar; Arthur Bradwell; Rafael Fonseca; D F Jelinek; S Vincent Rajkumar Journal: Lancet Date: 2010-05-15 Impact factor: 79.321
Authors: J-E Gottenberg; F Aucouturier; J Goetz; C Sordet; I Jahn; M Busson; J-M Cayuela; J Sibilia; X Mariette Journal: Ann Rheum Dis Date: 2006-03-28 Impact factor: 19.103
Authors: Robert A Kyle; Terry M Therneau; S Vincent Rajkumar; Dirk R Larson; Matthew F Plevak; Janice R Offord; Angela Dispenzieri; Jerry A Katzmann; L Joseph Melton Journal: N Engl J Med Date: 2006-03-30 Impact factor: 91.245
Authors: S Vincent Rajkumar; Robert A Kyle; Terry M Therneau; L Joseph Melton; Arthur R Bradwell; Raynell J Clark; Dirk R Larson; Matthew F Plevak; Angela Dispenzieri; Jerry A Katzmann Journal: Blood Date: 2005-04-26 Impact factor: 22.113
Authors: Guy Pratt; Stephen Harding; Roger Holder; Chris Fegan; Chris Pepper; David Oscier; Anne Gardiner; Arthur R Bradwell; Graham Mead Journal: Br J Haematol Date: 2008-11-11 Impact factor: 6.998
Authors: Ola Landgren; James J Goedert; Charles S Rabkin; Wyndham H Wilson; Kieron Dunleavy; Robert A Kyle; Jerry A Katzmann; S Vincent Rajkumar; Eric A Engels Journal: J Clin Oncol Date: 2010-01-04 Impact factor: 44.544
Authors: A Dispenzieri; R Kyle; G Merlini; J S Miguel; H Ludwig; R Hajek; A Palumbo; S Jagannath; J Blade; S Lonial; M Dimopoulos; R Comenzo; H Einsele; B Barlogie; K Anderson; M Gertz; J L Harousseau; M Attal; P Tosi; P Sonneveld; M Boccadoro; G Morgan; P Richardson; O Sezer; M V Mateos; M Cavo; D Joshua; I Turesson; W Chen; K Shimizu; R Powles; S V Rajkumar; B G M Durie Journal: Leukemia Date: 2008-11-20 Impact factor: 11.528
Authors: Thomas E Witzig; Matthew J Maurer; Mary J Stenson; Cristine Allmer; William Macon; Brian Link; Jerry A Katzmann; Mamta Gupta Journal: Am J Hematol Date: 2014-02-10 Impact factor: 10.047
Authors: James Ritchie; Lakhvir K Assi; Anne Burmeister; Richard Hoefield; Paul Cockwell; Philip A Kalra Journal: Clin J Am Soc Nephrol Date: 2015-03-30 Impact factor: 8.237
Authors: Xiaoli Deng; Cynthia S Crowson; S Vincent Rajkumar; Angela Dispenzieri; Dirk R Larson; Terry M Therneau; Eric L Matteson; Robert A Kyle; Jerry A Katzmann; Sherine E Gabriel; John M Davis Journal: J Rheumatol Date: 2015-01-15 Impact factor: 4.666
Authors: Thomas E Witzig; Matthew J Maurer; Thomas M Habermann; Brian K Link; Ivana N M Micallef; Grzegorz S Nowakowski; Stephen M Ansell; Joseph P Colgan; David J Inwards; Luis F Porrata; Svetomir N Markovic; Patrick B Johnston; Yi Lin; Carrie Thompson; Mamta Gupta; Jerry A Katzmann; James R Cerhan Journal: Am J Hematol Date: 2014-09-26 Impact factor: 10.047